374 related articles for article (PubMed ID: 25799995)
61. The SH2 domain containing inositol 5-phosphatase SHIP2 associates to the immunoreceptor tyrosine-based inhibition motif of Fc gammaRIIB in B cells under negative signaling.
Muraille E; Bruhns P; Pesesse X; Daëron M; Erneux C
Immunol Lett; 2000 Apr; 72(1):7-15. PubMed ID: 10789675
[TBL] [Abstract][Full Text] [Related]
62. Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition.
Moyo TK; Wilson CS; Moore DJ; Eischen CM
Oncogene; 2017 Aug; 36(32):4653-4661. PubMed ID: 28368423
[TBL] [Abstract][Full Text] [Related]
63. Targeting SYK kinase-dependent anti-apoptotic resistance pathway in B-lineage acute lymphoblastic leukaemia (ALL) cells with a potent SYK inhibitory pentapeptide mimic.
Uckun FM; Ek RO; Jan ST; Chen CL; Qazi S
Br J Haematol; 2010 May; 149(4):508-17. PubMed ID: 20151979
[TBL] [Abstract][Full Text] [Related]
64. Targeting of BCR-ABL1 and IRE1α induces synthetic lethality in Philadelphia-positive acute lymphoblastic leukemia.
Vieri M; Preisinger C; Schemionek M; Salimi A; Patterson JB; Samali A; Brümmendorf TH; Appelmann I; Kharabi Masouleh B
Carcinogenesis; 2021 Feb; 42(2):272-284. PubMed ID: 32915195
[TBL] [Abstract][Full Text] [Related]
65. Phosphorylation of the activation loop tyrosines is required for sustained Syk signaling and growth factor-independent B-cell proliferation.
Carsetti L; Laurenti L; Gobessi S; Longo PG; Leone G; Efremov DG
Cell Signal; 2009 Jul; 21(7):1187-94. PubMed ID: 19296913
[TBL] [Abstract][Full Text] [Related]
66. A novel SH2-containing phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase (SHIP2) is constitutively tyrosine phosphorylated and associated with src homologous and collagen gene (SHC) in chronic myelogenous leukemia progenitor cells.
Wisniewski D; Strife A; Swendeman S; Erdjument-Bromage H; Geromanos S; Kavanaugh WM; Tempst P; Clarkson B
Blood; 1999 Apr; 93(8):2707-20. PubMed ID: 10194451
[TBL] [Abstract][Full Text] [Related]
67. Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL.
Appelmann I; Rillahan CD; de Stanchina E; Carbonetti G; Chen C; Lowe SW; Sherr CJ
Blood; 2015 Feb; 125(9):1444-51. PubMed ID: 25499760
[TBL] [Abstract][Full Text] [Related]
68. Emerging BCR/ABL1 Mutations Under Treatment with Tyrosine Kinase Inhibitors in Paediatric Acute Lymphoblastic Leukaemia.
Molinos-Quintana A; Aquino V; Montero I; Pérez-de Soto C; García-Lozano R; Pérez-Simón JA; Pérez-Hurtado JM
Acta Haematol; 2015; 134(2):71-5. PubMed ID: 25895602
[TBL] [Abstract][Full Text] [Related]
69. Monophosphorylation of CD79a and CD79b ITAM motifs initiates a SHIP-1 phosphatase-mediated inhibitory signaling cascade required for B cell anergy.
O'Neill SK; Getahun A; Gauld SB; Merrell KT; Tamir I; Smith MJ; Dal Porto JM; Li QZ; Cambier JC
Immunity; 2011 Nov; 35(5):746-56. PubMed ID: 22078222
[TBL] [Abstract][Full Text] [Related]
70. Targeting Kinase-activating Genetic Lesions to Improve Therapy of Pediatric Acute Lymphoblastic Leukemia.
Franca R; Kuzelicki NK; Sorio C; Toffoletti E; Montecchini O; Poropat A; Rabusin M; Curci D; Paladin D; Stocco G; Decorti G
Curr Med Chem; 2018; 25(24):2811-2825. PubMed ID: 28748759
[TBL] [Abstract][Full Text] [Related]
71. The SH2 domain-containing inositol 5'-phosphatase (SHIP) recruits the p85 subunit of phosphoinositide 3-kinase during FcgammaRIIb1-mediated inhibition of B cell receptor signaling.
Gupta N; Scharenberg AM; Fruman DA; Cantley LC; Kinet JP; Long EO
J Biol Chem; 1999 Mar; 274(11):7489-94. PubMed ID: 10066815
[TBL] [Abstract][Full Text] [Related]
72. Fc epsilon receptor I-associated lyn-dependent phosphorylation of Fc gamma receptor IIB during negative regulation of mast cell activation.
Malbec O; Fong DC; Turner M; Tybulewicz VL; Cambier JC; Fridman WH; Daëron M
J Immunol; 1998 Feb; 160(4):1647-58. PubMed ID: 9469421
[TBL] [Abstract][Full Text] [Related]
73. Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Piccaluga PP; Paolini S; Martinelli G
Cancer; 2007 Sep; 110(6):1178-86. PubMed ID: 17701954
[TBL] [Abstract][Full Text] [Related]
74. Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of
Yang L; Qiu Q; Tang M; Wang F; Yi Y; Yi D; Yang Z; Zhu Z; Zheng S; Yang J; Pei H; Zheng L; Chen Y; Gou L; Luo L; Deng X; Ye H; Hu Y; Niu T; Chen L
Clin Cancer Res; 2019 Dec; 25(24):7527-7539. PubMed ID: 31439580
[TBL] [Abstract][Full Text] [Related]
75. Vav3 collaborates with p190-BCR-ABL in lymphoid progenitor leukemogenesis, proliferation, and survival.
Chang KH; Sanchez-Aguilera A; Shen S; Sengupta A; Madhu MN; Ficker AM; Dunn SK; Kuenzi AM; Arnett JL; Santho RA; Agirre X; Perentesis JP; Deininger MW; Zheng Y; Bustelo XR; Williams DA; Cancelas JA
Blood; 2012 Jul; 120(4):800-11. PubMed ID: 22692505
[TBL] [Abstract][Full Text] [Related]
76. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells.
Gobessi S; Laurenti L; Longo PG; Carsetti L; Berno V; Sica S; Leone G; Efremov DG
Leukemia; 2009 Apr; 23(4):686-97. PubMed ID: 19092849
[TBL] [Abstract][Full Text] [Related]
77. IKK-dependent activation of NF-κB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1.
Hsieh MY; Van Etten RA
Blood; 2014 Apr; 123(15):2401-11. PubMed ID: 24464015
[TBL] [Abstract][Full Text] [Related]
78. Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma.
Bernard S; Danglade D; Gardano L; Laguillier C; Lazarian G; Roger C; Thieblemont C; Marzec J; Gribben J; Cymbalista F; Varin-Blank N; Ledoux D; Baran-Marszak F
Int J Cancer; 2015 Jun; 136(12):2761-74. PubMed ID: 25388373
[TBL] [Abstract][Full Text] [Related]
79. A balance between B cell receptor and inhibitory receptor signaling controls plasma cell differentiation by maintaining optimal Ets1 levels.
Luo W; Mayeux J; Gutierrez T; Russell L; Getahun A; Müller J; Tedder T; Parnes J; Rickert R; Nitschke L; Cambier J; Satterthwaite AB; Garrett-Sinha LA
J Immunol; 2014 Jul; 193(2):909-920. PubMed ID: 24929000
[TBL] [Abstract][Full Text] [Related]
80. Liposomal Nanoparticles of a Spleen Tyrosine Kinase P-Site Inhibitor Amplify the Potency of Low Dose Total Body Irradiation Against Aggressive B-Precursor Leukemia and Yield Superior Survival Outcomes in Mice.
Uckun FM; Myers DE; Cheng J; Qazi S
EBioMedicine; 2015 Jun; 2(6):554-62. PubMed ID: 26285772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
